Phuturdex › Diseases › Pulmonary hypertension
Drugs in development · updated 30 October 2026
Pulmonary hypertension: drugs in development
As of 30 October 2026 there are 37 active clinical trials (recruiting or ongoing, phases I–III) on 38 drugs for pulmonary hypertension. 15 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Mosliciguat | III | 3 | NCT07816185 |
| Treprostinil Palmitil Inhalation Powder | III | 2 | NCT07234032 |
| L606 | III | 1 | NCT07285655 |
| Ralinepag | III | 1 | NCT03683186 |
| TNX-103 | III | 1 | NCT05983250 |
| TX000045 | II | 2 | NCT07473700 |
| APL-9796 | II | 1 | NCT06846554 |
| Frespaciguat | II | 1 | NCT05612035 |
| GM-CSFGranulocyte-Macrophage Colony-Stimulating Factor | II | 1 | NCT03630211 |
| HS235 | I–II | 1 | NCT07123779 |
| PF-07868489 | II | 1 | NCT07073820 |
| REGN13335 | II | 1 | NCT07318597 |
| ROC-101 | II | 1 | NCT07175038 |
| Telaglenastat Hydrochloride | I–II | 1 | NCT07223528 |
| F230 | I | 1 | NCT06899815 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| SelexipagUptravi® | III | 2 | NCT05179876 |
| SotaterceptACE-011, Winrevair® | III | 2 | NCT07839585 |
| TadalafilChewtadzy®, Tadliq® | III | 2 | NCT05844462 |
| DoxycyclineDoxycyclin, Lymepak® | III | 1 | NCT05473520 |
| MacitentanOpsumit®, Macitentan Accord® | III | 1 | NCT05179876 |
| RiociguatBAY63-2521, Adempas® | III | 1 | NCT02562235 |
| AlemtuzumabCampath, Lemtrada® | II | 1 | NCT03630211 |
| Anti-Thymocyte Globulin | II | 1 | NCT03630211 |
| BelzutifanWelireg® | II | 1 | NCT07895966 |
| ColchicineColchicin, Lodoco® | II | 1 | NCT07907757 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 1 | NCT03630211 |
| EmpagliflozinJardiance | II | 1 | NCT06570473 |
| MesnaUromitexan, Mesnex® | II | 1 | NCT03630211 |
| Norepinephrine | II | 1 | NCT07614438 |
| PioglitazoneActos, Pioglitazone Accord® | II | 1 | NCT06336798 |
Sorted by most advanced phase and number of active trials. Showing 15 of 23 drugs.
All 38 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Arterial pulmonary hypertension 27 drugs
- Cardiovascular disease 71 drugs
- Heart failure 104 drugs
- Hypoxia 20 drugs
- Right ventricular dysfunction 5 drugs
- Chronic obstructive pulmonary disease 89 drugs
- Primary pulmonary hypertension 11 drugs
- Arterial hypertension 119 drugs
- Interstitial lung disease 65 drugs
- Acute lung injury 9 drugs
- Hereditary hemorrhagic telangiectasia 8 drugs
Broader categories
- Respiratory disease 57 drugs
- Arterial hypertension 119 drugs
- Lung disease 104 drugs
- Vascular disease 16 drugs
- Cardiovascular disease 71 drugs
- Obstructive lung disease 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006976 “Hypertension, Pulmonary”.